Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot2 - STU 1 ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot2 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Example Evidence: Percentage of Participants With Potentially Related Adverse Events at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312

version: 26; Last updated: 2025-08-18 13:22:42+0000

Profile: ComparativeEvidence

ArtifactPublicationStatus: Active

url: https://fevir.net/resources/Evidence/367953

identifier: FEvIR Object Identifier/367953, FEvIR Linking Identifier/NCT03640312-otherOutcomeMeasure-1-OutcomeAnalysis-12-BetweenGroupAnalysis-OG000-OG001

name: NCT03640312_otherOutcomeMeasure_1_OutcomeAnalysis_12_BetweenGroupAnalysis_OG000_OG001

title: Percentage of Participants With Potentially Related Adverse Events at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312

citeAs:

Percentage of Participants With Potentially Related Adverse Events at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367953. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367953. Computable resource at: https://fevir.net/resources/Evidence/367953#json.

status: Active

author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter:

publisher: Computable Publishing LLC

contact: support@computablepublishing.com

copyright:

https://creativecommons.org/licenses/by-nc-sa/4.0/

description:

This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.

variableDefinition

note:

All randomized participants

variableRole: Population

intended: Group NCT03640312 Eligibility Criteria

variableDefinition

description:

Group Assignment: QUARTET LDQT vs. Candesartan

variableRole: Exposure

comparatorCategory: Candesartan

observed: Group Assignment: Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States. QUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks. vs. Patients randomized to the comparison arm took a once daily 8mg candesartan. Candesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.

variableDefinition

variableRole: Outcome

observed: Percentage of Participants With Potentially Related Adverse Events at 12 weeks (NCT03640312)

statistic

note:

Outcome Analysis NonInferiority Type: Superiority

statisticType: Risk Difference (RD)

quantity: -0.15 Participants

attributeEstimate

type: standard error of the mean

quantity: 0.09 Participants

attributeEstimate

type: P-value

quantity: 0.21

attributeEstimate

note:

CI Number of Sides: 2-Sided

type: Confidence interval

level: 0.95

range: -0.33-0.03 Participants

ModelCharacteristics

-Code
*Chi-squared